Dutch-Swiss biotech startup Cradle has raised a $24 million in Series A funding. The company, which leverages the potential of generative AI for precise bioengineering, has convinced Index Ventures and Kindred Capital, as well as high-level angel investors, such as Tom Glocer, former CEO of Thomson Reuters and Lead Director of pharma giant Merck.
![Cradle raises $24m for GenAI biotech platform](https://republic-of-innovation.ch/wordpress/wp-content/uploads/2023/11/Cradle-labo-biotech-630x420.jpg)